The agency teamed up with the software company to develop platforms and networks to collect de-identified data.
stock.adobe.com
FDA previously teamed up with Workflow Services to build out a program to collect de-identified data. Now, 100 days into the partnership, Workflow Services is releasing data that shows it has hit a milestone.
During this time period, Workflow Services says that it has increased the number of users on its platform, built partnerships with both industry trade organizations and test manufacturers, and built up its team, according to a press release.1 Earlier this year, Workflow Services expanded its leadership team to better serve the goals of its partnership with FDA.
In a press release, Workflow Services CEO Kevin Houlihan said, “The retail pharmacy setting is rapidly evolving. It's moving in ways and at a pace that it never really has. The FDA's Diagnostic Data Program signals that point-of-care testing in non-traditional settings is here to stay and will only continue to grow. It's why our team has been moving fast to expand our footprint, optimize our solution, and help pharmacies accelerate their plans to put healthcare and wellness services at the forefront of their retail operations."
Workflow Services’ COO Elise Miller Hoffman also said, “We are growing and adding team members with a wealth of industry knowledge, enabling us to be a stronger, more receptive, and agile partner to our pharmacy customers.”
FDA entered into its partnership with Workflow Services as part of a program to collect de-identified data. The agency is developing ways to both collect and transmit patient data while also being able to maintain patient privacy. This issue has become much more important in recent years as more and more companies are using AI and algorithm-based programs to collect, analyze, and sort patient data. Due to the unique nature of the medical industry, however, regulators have struggled to manage this data collection while also maintaining the legal requirements for patient privacy.
This partnership has a goal of expanding FDA’s ability to collect real-world data for analysis. For the agency, this is an important step in becoming better at identifying viral transmission locations and preventing outbreaks.
Workflow Services is a healthcare software developed by its parent company, ImageMoverMD and is headquartered in Madison, Wisconsin.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.